blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3738584

EP3738584 - GRANULATE CONTAINING ESLICARBAZEPINE ACETATE, ITS PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING IT, AND THEIR USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.05.2023
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  27.05.2022
FormerGrant of patent is intended
Status updated on  18.01.2022
FormerRequest for examination was made
Status updated on  06.08.2021
FormerThe application has been published
Status updated on  16.10.2020
Most recent event   Tooltip19.01.2024Lapse of the patent in a contracting state
New state(s): MC		published on 21.02.2024  [2024/08]
Applicant(s)For all designated states
MEDITOP Gyógyszeripari Korlátolt Felelösségü Társaság
Ady Endre utca 1.
2097 Pilisborosjenö / HU
[2022/26]
Former [2020/47]For all designated states
MEDITOP Gyogyszeripari Korlatolt Felelossegu Tarsasag
Ady Endre utca 1.
2097 Pilisborosjeno / HU
Inventor(s)01 / Fekete, Pál
Csernyus u. 15.
1141 Budapest / HU
02 / Bajdik, János
Huszka Mihály u. 20.
2143 Kistarcsa / HU
03 / Gál, Lívia
Kömény u. 8.
2000 Szentendre / HU
04 / Öszi, Zsolt
Kiss Ernö u. 7/A.
2220 Vecsés / HU
 [2022/26]
Former [2020/47]01 / Fekete, Pál
Csernyus u. 15.
1141 Budapest / HU
02 / Bajdik, János
Huszka Mihály u. 20.
2143 Kistarcsa / HU
03 / Gál, Lívia
Kömény u. 8.
2000 Szentendre / HU
04 / szi, Zsolt
Kiss Ern u. 7/A.
2220 Vecsés / HU
Representative(s)Kovári, Zoltán
Kovári Patent and Trademark Attorneys' LLC
(Kovári LLC)
Attila út 125
1012 Budapest / HU
[2020/47]
Application number, filing date20174336.613.05.2020
[2020/47]
Priority number, dateHU2019000015314.05.2019         Original published format: HU 1900153
[2020/47]
Filing languageHU
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3738584
Date:18.11.2020
Language:EN
[2020/47]
Type: B1 Patent specification 
No.:EP3738584
Date:29.06.2022
Language:EN
[2022/26]
Search report(s)(Supplementary) European search report - dispatched on:EP13.10.2020
ClassificationIPC:A61K9/16, A61K9/20, A61K31/55, A61K9/48, A61P25/08
[2022/01]
CPC:
A61K9/1652 (EP); A61K31/55 (EP,HU); A61K9/16 (HU);
A61K9/2054 (EP); A61P25/08 (EP); A61K9/4866 (EP)
Former IPC [2020/47]A61K9/16, A61K9/20, A61K31/55, A61P25/08, A61K48/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/36]
Former [2020/47]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:GRANULATE ENTHALTEND ESLICARBAZEPINACETAT, SOWIE DEREN HERSTELLUNG, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNG[2020/47]
English:GRANULATE CONTAINING ESLICARBAZEPINE ACETATE, ITS PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING IT, AND THEIR USE[2020/47]
French:GRANULES CONTENANT DE L'ACETATE D'ESLICARBAZEPINE, LEUR PRODUCTION, PRÉPARATION ET USAGE[2020/47]
Examination procedure18.05.2021Examination requested  [2021/36]
18.05.2021Date on which the examining division has become responsible
31.05.2021Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time
09.07.2021Amendment by applicant (claims and/or description)
26.01.2022Communication of intention to grant the patent
29.03.2022Fee for grant paid
29.03.2022Fee for publishing/printing paid
25.04.2022Receipt of the translation of the claim(s)
Opposition(s)30.03.2023No opposition filed within time limit [2023/23]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
12.07.2021Request for further processing filed
12.07.2021Full payment received (date of receipt of payment)
Request granted
11.08.2021Decision despatched
12.07.2021Request for further processing filed
12.07.2021Full payment received (date of receipt of payment)
Request granted
11.08.2021Decision despatched
Fees paidRenewal fee
18.05.2022Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL29.06.2022
CZ29.06.2022
EE29.06.2022
LT29.06.2022
LV29.06.2022
MC29.06.2022
RO29.06.2022
SK29.06.2022
SM29.06.2022
BG29.09.2022
GR30.09.2022
IS29.10.2022
[2024/08]
Former [2023/22]AL29.06.2022
CZ29.06.2022
EE29.06.2022
LT29.06.2022
LV29.06.2022
RO29.06.2022
SK29.06.2022
SM29.06.2022
BG29.09.2022
GR30.09.2022
IS29.10.2022
Former [2023/17]AL29.06.2022
EE29.06.2022
LT29.06.2022
LV29.06.2022
RO29.06.2022
SK29.06.2022
SM29.06.2022
BG29.09.2022
GR30.09.2022
IS29.10.2022
Former [2023/12]EE29.06.2022
LT29.06.2022
LV29.06.2022
RO29.06.2022
SK29.06.2022
SM29.06.2022
BG29.09.2022
GR30.09.2022
IS29.10.2022
Former [2023/09]EE29.06.2022
LT29.06.2022
LV29.06.2022
RO29.06.2022
SK29.06.2022
SM29.06.2022
BG29.09.2022
GR30.09.2022
Former [2022/49]LT29.06.2022
LV29.06.2022
BG29.09.2022
GR30.09.2022
Former [2022/47]LT29.06.2022
Documents cited:Search[XD]WO2009054743  (BIAL PORTELA & CA SA [PT], et al) [XD] 1,3,4,6-8,10,12-14 * page 2, line 4 - page 6, line 32 ** claims 1-72 *;
 [XDY]WO2017103876  (JUBILANT GENERICS LTD [IN]) [XD] 1-4,6-14 * page 1, line 3 - line 9 * * page 3, line 10 - page 7, line 14 * * page 8, line 7 - line 8 * * page 8, line 33 - page 9, line 3 * * page 9, line 15 - page 10, line 12 * * page 12, line 11 - line 20 * * examples 1,3,4,6-9 * * table - * * claim - * [Y] 5;
 [Y]  - Anonymous, "Low-Substituted Hydroxypropyl Cellulose NF L-HPC", (20050801), URL: http://www.elementoorganika.ru/files/lhpc.pdf, (20171212), XP055434172 [Y] 5 * the whole document * * page 11 * * page 17 *
 [Y]  - Anonymous, "NBD Grades (New Binder Disintegrant)", Shin Etsu - Brochure, (20111001), URL: http://www.dalian-diligence.com/images/NBD-EN.pdf, (20200608), XP055702130 [Y] 5 * the whole document * * section "Benefits of NBD" * * section "Properties of NBD" * * section "Product specifications" *
 [A]  - ROWE R C ET AL, Handbook of pharmaceutical excipients, Hydroxypropyl Cellulose, Low-substituted, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS [U.A.], LONDON [U.A.], PAGE(S) 341 - 343, (20060101), ISBN 978-1-58212-058-4, XP002547079 [A] 1-14 * the whole document * * section "6 Functional Category" *
by applicantUS2009110722
 US8372431
 WO2017103876
    - International Journal of Pharmacy and Pharmaceutical Sciences, (20130000), vol. 5, no. 4, pages 192 - 194
    - Pharmaceutical Technology, JATEPress, (20090000), pages 265 - 274
    - DR ATTILA DEVAY, The Theory and Practice of Pharmaceutical Technology, University of Pecs, (20130000), pages 355 - 387
    - Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, (19890000), vol. 1, pages 131 - 193
    - SHAYNE COX GAD, Pharmaceutical Manufacturing Handbook, Production and Processes, John Wiley & Sons, Inc., (20080000), page 928
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.